ZA200601770B - Combination therapy for glycaemic - Google Patents

Combination therapy for glycaemic Download PDF

Info

Publication number
ZA200601770B
ZA200601770B ZA200601770A ZA200601770A ZA200601770B ZA 200601770 B ZA200601770 B ZA 200601770B ZA 200601770 A ZA200601770 A ZA 200601770A ZA 200601770 A ZA200601770 A ZA 200601770A ZA 200601770 B ZA200601770 B ZA 200601770B
Authority
ZA
South Africa
Prior art keywords
composition
glutaminyl
substance
treatment
diabetes mellitus
Prior art date
Application number
ZA200601770A
Other languages
English (en)
Inventor
Demuth Hans-Ulrich
Hoffmann Matthias
Glund Konrad
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of ZA200601770B publication Critical patent/ZA200601770B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ZA200601770A 2003-09-02 2006-02-28 Combination therapy for glycaemic ZA200601770B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02

Publications (1)

Publication Number Publication Date
ZA200601770B true ZA200601770B (en) 2007-07-25

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200601770A ZA200601770B (en) 2003-09-02 2006-02-28 Combination therapy for glycaemic

Country Status (14)

Country Link
US (1) US20060287251A1 (OSRAM)
EP (1) EP1663200A2 (OSRAM)
JP (1) JP2007504213A (OSRAM)
KR (1) KR20060119927A (OSRAM)
CN (1) CN1845731A (OSRAM)
AU (1) AU2004267955A1 (OSRAM)
BR (1) BRPI0413204A (OSRAM)
CA (1) CA2536432A1 (OSRAM)
EA (1) EA200600356A1 (OSRAM)
IL (1) IL173844A0 (OSRAM)
MX (1) MXPA06002127A (OSRAM)
NO (1) NO20061085L (OSRAM)
WO (1) WO2005020983A2 (OSRAM)
ZA (1) ZA200601770B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
JP2013523620A (ja) * 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
SG11201401175SA (en) * 2011-10-28 2014-09-26 Sanofi Aventis Deutschland Treatment protocol of diabetes type 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
DE122008000018I1 (de) * 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
IL163629A0 (en) * 2002-02-28 2005-12-18 Prosidion Ltd Glutaminyl derivatives and pharmaceutical compositions containing the same
AU2003293311A1 (en) * 2002-09-18 2004-04-23 Prosidion Ltd. Secondary binding site of dipeptidyl peptidase iv (dp iv)

Also Published As

Publication number Publication date
WO2005020983A3 (en) 2005-07-28
IL173844A0 (en) 2006-07-05
KR20060119927A (ko) 2006-11-24
CN1845731A (zh) 2006-10-11
CA2536432A1 (en) 2005-03-10
WO2005020983A2 (en) 2005-03-10
NO20061085L (no) 2006-05-31
JP2007504213A (ja) 2007-03-01
US20060287251A1 (en) 2006-12-21
MXPA06002127A (es) 2006-05-31
EP1663200A2 (en) 2006-06-07
EA200600356A1 (ru) 2006-08-25
BRPI0413204A (pt) 2006-10-03
AU2004267955A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
US7078397B2 (en) Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US7935723B2 (en) Use of organic compounds
US7241756B2 (en) Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
CA2622579C (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
ES2390231T3 (es) Agentes farmacéuticos concomitantes y su uso
WO2007149797A2 (en) Use of organic compounds
Ahrén et al. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism
KR20090038908A (ko) 대사 장애의 조합 치료
US20090054512A1 (en) Use of organic compounds
US20050014732A1 (en) Combination of an aldosterone receptor antagonist and an anti-diabetic agent
JP2012092136A (ja) 哺乳動物の血糖値低下のためのジペプチジルペプチダーゼｉｖエフェクターの使用
KR20120016051A (ko) 제약 조성물
CA2581298A1 (en) Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
ZA200601770B (en) Combination therapy for glycaemic
SK287823B6 (sk) Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2- methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-2,4-dione and sub-maximal amount of glimepiride and use thereof
Del Prato Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes
McIntyre et al. Vildagliptin